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LCNEC

:   large cell neuroendocrine carcinoma

PSM

:   propensity score matching

SEER

:   Surveillance, Epidemiology, and End Results

1. INTRODUCTION {#cam42188-sec-0005}
===============

Large cell neuroendocrine carcinoma (LCNEC) of the lung, accounting for 3% of all lung cancer cases, is a rare, aggressive tumor with poor prognosis and high recurrence rate.[1](#cam42188-bib-0001){ref-type="ref"} LCNEC closely correlated with smoke status, almost 90% of all the cases have smoke history. LCNEC was classified as a subtype of large cell carcinomas according to the World Health Organization (WHO) classification of lung tumors, while, in the 2015 WHO classification, it was classified as a neuroendocrine neoplasm along with small‐cell lung cancer. Considering LCNEC shares many similarities with SCLC, such as therapeutic targets and gene alterations,[2](#cam42188-bib-0002){ref-type="ref"} SCLC‐based chemotherapy was expected to achieve similar effectiveness in patients with LCNEC. Unfortunately, the reported prognoses of LCNEC treated with SCLC‐based chemotherapy are heterogeneous.[3](#cam42188-bib-0003){ref-type="ref"}, [4](#cam42188-bib-0004){ref-type="ref"} By now, no standard treatment regimen has been developed. LCNEC should be treated in a manner similar to that used for small cell lung cancer or similar to NSCLC is still on debating.

Considering the optimum treatment for LCNEC patients remain undefined, to improve prognoses in patients with LCNEC, this study investigated the effect of different treatments for LCNEC based on the data obtained from the SEER database.

2. MATERIALS AND METHODS {#cam42188-sec-0006}
========================

2.1. Database and date extraction items {#cam42188-sec-0007}
---------------------------------------

The SEER database is an opening database containing frequency and survival data. SEER\*Stat 8.5.0 software was applied for data extraction. The variables including CS Schema v0204+ (lung), ICD‐0‐3 Hist/behav (8013/3), and AJCC 6th were used to extract the cases diagnosed with LCNEC registered in the SEER database.

The demographic and clinicopathologic characteristics were selected as follows: race, age, gender, grade, AJCC stage, AJCC T stage, AJCC N stage, AJCC M stage, surgery, radiation, chemotherapy, follow‐up time, and outcome status. Based on the information of cases provided by the SEER database, we defined overall survival (OS) as the time from diagnosis to death from any cause, and patients alive were censored at the time of the last recording. We deleted the cases that do not contain all these data and obtained 2594 cases for further analysis.

2.2. Propensity score matching (PSM) {#cam42188-sec-0008}
------------------------------------

A propensity 1:1 matched analysis was conducted to reduce possible bias to a minimum in this study. Propensity scores were calculated using logistic regression model for each patient in the comparing groups. The covariates included in the regression were race, age, gender, grade, AJCC stage, AJCC T stage, AJCC N stage, AJCC M stage, surgery, radiation, and chemotherapy. Patients in two groups were matched based on the propensity score (0.02). Covariates balance between two groups was examined by χ^2^ test. The survival comparisons were then performed for the propensity score‐matched patients using the Kaplan‐Meier method.

2.3. Statistical analysis {#cam42188-sec-0009}
-------------------------

SPSS (24.0) was used for statistical analysis. Overall survival was estimated using the Kaplan‐Meier method and compared by log‐rank test. One‐way ANOVA was used to test the statistical difference of race, age, gender, grade, AJCC stage, AJCC T stage, AJCC N stage, AJCC M stage, surgery, radiation, and chemotherapy between the groups. Univariate and multivariate Cox proportional hazard models, with hazard ratios (HRs) and 95% confidence intervals (CIs) reported, were applied to identify factors that associated with OS. The values of *P* \< 0.05 were considered statistically significant.

3. RESULTS {#cam42188-sec-0010}
==========

3.1. Patients' characteristics {#cam42188-sec-0011}
------------------------------

The characteristics of the 2594 LCNEC patients were shown in Table [1](#cam42188-tbl-0001){ref-type="table"}. 2171 LCNEC patients were white people, the elderly patients were accounted for 1848, and there were 1465 males and 1129 females. The patients with stage I, II, III, and IV were 569, 135, 525, and 1365, respectively.

###### 

Patients' characteristics

  Variable         Value (2594)          
  ---------------- -------------- ------ ------
  Race                                   
  White            463            1708   2171
  Black            71             242    313
  Others/unknown   24             86     110
  Age                                    
  \<60             198            548    746
  ≥60              360            1488   1848
  Gender                                 
  Male             284            1181   1465
  Female           274            855    1129
  Grade                                  
  I                3              9      12
  II               10             21     31
  III              252            632    884
  IV               76             213    289
  Unknown          217            1161   1378
  TNM                                    
  I                279            290    569
  II               46             89     135
  III              104            421    525
  IV               129            1236   1365
  T                                      
  Tx               20             203    223
  T0               2              22     24
  T1               192            351    543
  T2               234            593    827
  T3               24             113    137
  T4               86             754    840
  N                                      
  Nx               7              90     97
  N0               344            616    960
  N1               54             184    238
  N2               118            800    918
  N3               35             346    381
  M                                      
  M0               429            800    1229
  M1               129            1236   1365
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3.2. Identifying adverse prognosis factors for LCNEC patients {#cam42188-sec-0012}
-------------------------------------------------------------

LCNEC is an aggressive tumor with grim prognosis; moreover, the diagnostic rate was increasing in recent years (Figure [S1](#cam42188-sup-0001){ref-type="supplementary-material"}A). It is necessary to explore the factors that influenced long‐term survival of patients with LCNEC. Univariate and multivariate Cox regression analyses were performed to determine prognostic factors (Table [2](#cam42188-tbl-0002){ref-type="table"}). The results suggested that race, grade, T1, and N1 were not considered as independent adverse prognostic factors for LCNEC patients. However, other characteristics including gender \[male vs female, 1 vs 0.847 (0.775‐0.926)\], age \[\<60 vs ≥ 60, 1 vs 1.396 (1.264‐1.542)\], TNM stage{\[I vs II, 1 vs 1.525 (1.145‐2.032)\]; \[I vs III, 1 vs 1.762 (1.444‐2.149)\]; \[I vs IV, 1 vs 3.831 (3.199‐4.590)\]}, T stage {\[T0 vs T2, 1 vs 1.638 (1.065‐2.518)\]; \[T0 vs T3, 1 vs 1.985 (1.250‐3.154)\]; \[T0 vs T4, 1 vs 2.145 (1.400‐3.285)\] ; \[T0 vs Tx, 1 vs 1.650 (1.060‐2.569)\]}, N stage {\[N0 vs N2, 1 vs 1.253 (1.096‐1.432)\]; \[N0 vs N3, 1 vs 1.433 (1.226‐1.674)\]; \[N0 vs Nx, 1 vs 1.516 (1.188‐1.934)\]}, M stage \[M0 vs M1, 1 vs 3.831 (3.199‐4.590)\] were all identified as independent prognostic factors.

###### 

Univariate and multivariate analyses for LCNEC patients

  Characteristic   Univariate Cox regression   Multivariate Cox regression                         
  ---------------- --------------------------- ----------------------------- --------------------- -----------
  Race                                                                                             
  White            1.00 Reference                                            1.00 Reference         
  Black            0.930 (0.813‐1.064)         0.290                         0.911 (0.795‐1.044)   0.181
  Others           1.013 (0.816‐1.259)         0.904                         0.832 (0.669‐1.034)   0.097
  Age                                                                                              
  \<60             1.00 Reference                                            1.00 Reference         
  ≥60              1.306 (1.184‐1.440)         **0.000**                     1.396 (1.264‐1.542)   **0.000**
  Gender                                                                                           
  Male             1.00 Reference                                            1.00 Reference         
  Female           0.816 (0.747‐0.891)         **0.000**                     0.847 (0.775‐0.926)   **0.000**
  Grade                                                                                            
  I                1.00 Reference                                            1.00 Reference         
  II               0.760 (0.348‐1.660)         0.492                         1.007 (0.460‐2.205)   0.985
  III              0.901 (0.467‐1.740)         0.757                         1.205 (0.623‐2.332)   0.579
  IV               0.974 (0.500‐1.899)         0.938                         1.283 (0.657‐2.505)   0.466
  Unknown          1.524 (0.791‐2.937)         0.208                         1.450(0.751‐2.800)    0.268
  TNM                                                                                              
  I                1.00 Reference                                            1.00 Reference         
  II               1.678 (1.323‐2.129)         **0.000**                     1.525 (1.145‐2.032)   **0.004**
  III              2.591 (2.228‐3.014)         **0.000**                     1.762 (1.444‐2.149)   **0.000**
  IV               5.488 (4.796‐6.279)         **0.000**                     3.831 (3.199‐4.590)   **0.000**
  T                                                                                                
  T0               1.00 Reference                                            1.00 Reference         
  T1               0.593 (0.385‐0.913)         **0.017**                     1.456 (0.940‐2.256)   0.093
  T2               0.831 (0.543‐1.272)         0.395                         1.638 (1.065‐2.518)   **0.025**
  T3               1.124 (0.712‐1.774)         0.617                         1.985 (1.250‐3.154)   **0.004**
  T4               1.779 (1.164‐2.720)         **0.008**                     2.145 (1.400‐3.285)   **0.000**
  Tx               1.640 (1.056‐2.546)         **0.028**                     1.650 (1.060‐2.569)   **0.027**
  N                                                                                                
  N0               1.00 Reference                                            1.00 Reference         
  N1               1.621 (1.374‐1.913)         **0.000**                     1.118 (0.919‐1.359)   0.264
  N2               2.357 (2.119‐2.623)         **0.000**                     1.253 (1.096‐1.432)   **0.001**
  N3               3.076 (2.685‐3.523)         **0.000**                     1.433 (1.226‐1.674)   **0.000**
  Nx               3.609 (2.884‐4.516)         **0.000**                     1.516 (1.188‐1.934)   **0.001**
  M                                                                                                
  M0               1.00 Reference                                            1.00 Reference         
  M1               3.373 (3.068‐3.708)         **0.000**                     3.831 (3.199‐4.590)   **0.000**

Bold indicates the significance value (*P* \< 0.05).
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3.3. Surgery benefit stage I, II, and III LCNEC patients' prognosis {#cam42188-sec-0013}
-------------------------------------------------------------------

When cancer patients are diagnosed at early stage (stage I and II), patients were recommended to perform surgery to obtain better prognosis. To determine whether surgical treatment would benefit the early stage LCNEC patients' prognoses or not, we firstly divided the stage I and II patients into surgery and non‐surgery group, PSM method was conducted to reduce the differences of variables between groups (Table [3](#cam42188-tbl-0003){ref-type="table"}). We found surgery benefit early stage patients' prognoses (Figure [1](#cam42188-fig-0001){ref-type="fig"}A,B). We also found stage III LCNEC patients who undergone surgery had better prognoses than the non‐surgery patients (Figure [1](#cam42188-fig-0001){ref-type="fig"}C‐F, Tables [S1](#cam42188-sup-0001){ref-type="supplementary-material"} and [S2](#cam42188-sup-0001){ref-type="supplementary-material"}). In clinic, the stage IV lung cancer patients are no longer suitable to perform surgery; however, we found that there are still some stage IV LCNEC patients have undergone surgery (Table [4](#cam42188-tbl-0004){ref-type="table"}). Because the variable differences such as age (*P* = 0.000), radiation (*P* = 0.029), and chemotherapy (*P* = 0.025) between the groups were exist even PSM method was conducted (Figure [S1](#cam42188-sup-0001){ref-type="supplementary-material"}B,C, Table [S3](#cam42188-sup-0001){ref-type="supplementary-material"}), it is uncertainty that whether surgery would benefit the prognoses or not for stage IV LCNEC patients. The results demonstrated that surgery benefited the stage I, II, and III LCNEC patients; patients at those stages should perform surgery to achieve better prognoses.

###### 

Characteristics among surgical and non‐surgical early stage LCNEC patients before and after propensity score matching

  Characteristics   Before PSM analysis   *P*   After PSM analysis   *P*        
  ----------------- --------------------- ----- -------------------- ----- ---- -------
  Race                                          0.105                           0.158
  White             85                    503                        59    49    
  Black             20                    71                         16    21    
  Others            2                     23                         1     6     
  Age                                           **0.001**                       0.339
  ≥60               91                    736                        61    56    
  ＜60              16                    251                        15    20    
  Gender                                        0.946                           0.050
  Male              55                    309                        39    27    
  Female            52                    288                        37    49    
  Grade                                         **0.000**                       0.181
  I                 0                     3                          0     2     
  II                1                     16                         1     3     
  III               33                    327                        30    18    
  IV                12                    102                        11    15    
  Unknown           61                    149                        34    38    
  TNM                                           0.509                           0.851
  I                 84                    485                        57    58    
  II                23                    112                        19    18    
  T                                             **0.032**                       0.628
  Tx                0                     0                          0     0     
  T0                0                     0                          0     0     
  T1                44                    284                        30    32    
  T2                51                    287                        36    36    
  T3                12                    26                         10    8     
  T4                0                     0                          0     0     
  N                                             0.255                           0.808
  Nx                0                     0                          0     0     
  N0                96                    511                        67    66    
  N1                11                    86                         9     10    
  N2                0                     0                          0     0     
  N3                0                     0                          0     0     
  Radiation                                     **0.000**                       1.000
  Yes               62                    52                         31    31    
  No                45                    545                        45    45    
  Chemotherapy                                  0.366                           0.184
  Yes               39                    191                        25    33    
  No                68                    406                        51    43    

Bold indicates the significance value (*P* \< 0.05).
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![Surgery benefited stage I, II, and III LCNEC patients' prognoses. A, Surgery patients achieved better prognoses than non‐surgery patients in stage I and II LCNEC patients (*P *= 0.000). B, Surgery patients achieved better prognoses than non‐surgery patients in stage I and II LCNEC patients after PSM was conducted (*P* = 0.000). C, Surgery patients achieved better prognoses than non‐surgery patients in stage III A LCNEC patients (*P* = 0.005). D, Surgery patients achieved better prognoses than non‐surgery patients in stage III A LCNEC patients after PSM was conducted (*P* = 0.001). E, Surgery patients achieved better prognoses than non‐surgery patients in stage III B LCNEC patients (*P* = 0.009). F, Surgery patients achieved better prognoses than non‐surgery patients in stage III B LCNEC patients after PSM was conducted (*P* = 0.017)](CAM4-8-2979-g001){#cam42188-fig-0001}

###### 

Treatment values of LCNEC patients in different stages

  Treatment                  Value              
  -------------------------- ------- ---- ----- -----
  Palliative treatment       25      8    85    337
  Radiation                  32      3    33    184
  Chemotherapy               6       6    79    346
  Chemoradiation             21      6    188   411
  Surgery                    354     37   47    23
  Surgery + Radiation        13      2    5     14
  Surgery + Chemotherapy     107     47   41    18
  Surgery + Chemoradiation   11      26   47    32
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3.4. Combination treatment of surgery and chemotherapy benefit stage I, II, III LCNEC patients more than the other treatments {#cam42188-sec-0014}
-----------------------------------------------------------------------------------------------------------------------------

LCNEC is an aggressive tumor with high rate of recurrence even after complete surgical resection in its early stage; therefore, surgery alone is not sufficient to treat patients with LCNEC. We firstly compared surgery alone with surgery combining with radiation, surgery combining with chemotherapy and surgery combining with chemoradiation, respectively. When surgery alone compared with the combination treatment of surgery and radiation or the combination treatment of surgery and chemotherapy, there were differences of variables between the groups (Tables [S4](#cam42188-sup-0001){ref-type="supplementary-material"} and [S5](#cam42188-sup-0001){ref-type="supplementary-material"}); it was uncertainty that whether those combination treatments would achieve better benefit than surgery alone or not (Figure [S2](#cam42188-sup-0001){ref-type="supplementary-material"}A‐D). However, we found, compared with surgery alone, the combination treatment of surgery and chemoradiation achieved better prognoses for stage I, II, and III LCNEC patients (Figure [2](#cam42188-fig-0002){ref-type="fig"}A,B, Table [5](#cam42188-tbl-0005){ref-type="table"}).

![The combination treatment of surgery and chemotherapy benefited stage I, II, and III LCNEC patients better than the other treatments. A, Compared with surgery alone, surgery combining with chemoradiation had no benefit for stage I, II, and III LCNEC patients (*P* = 0.555). B, Surgery combining with chemoradiation achieved better prognosis than surgery alone in stage I, II, and III LCNEC patients after PSM was conducted (*P* = 0.044). C, Surgery combining with chemotherapy achieved better prognosis than surgery combining with radiation (*P* = 0.035). D, Compared with surgery combining with chemoradiation, surgery combining with chemotherapy achieved better prognosis for patients (*P* = 0.025). E, Surgery combining with chemotherapy did not have significant difference when compared with surgery combining with chemoradiation in improving patients' prognoses after the differences of variables between the groups were reduced (*P* = 0.499). F, Survival comparisons between treatments showed surgery combining with chemotherapy have advantage in improving patients' prognoses than the other treatments (*P* = 0.033)](CAM4-8-2979-g002){#cam42188-fig-0002}

###### 

Characteristics among surgery alone (S) and surgery combining with chemoradiation (S + C + R) in stage I, II, and III LCNEC patients before and after propensity score matching

  Characteristics   Before PSM analysis   *P*   After PSM analysis   *P*        
  ----------------- --------------------- ----- -------------------- ----- ---- -------
  Race                                          0.380                           0.891
  White             368                   73                         62    62    
  Black             54                    7                          6     7     
  Others            16                    4                          5     4     
  Age                                           **0.001**                       1.000
  ≥60               338                   50                         47    47    
  ＜60              100                   34                         26    26    
  Gender                                        0.465                           0.393
  Male              226                   47                         49    44    
  Female            212                   37                         24    29    
  Grade                                         0.229                           0.192
  I                 3                     1                          1     1     
  II                13                    2                          2     2     
  III               236                   51                         33    40    
  IV                59                    13                         12    13    
  Unknown           127                   17                         25    17    
  TNM                                           **0.000**                       0.411
  Stage I           354                   11                         12    11    
  Stage II          37                    26                         33    21    
  Stage III         47                    47                         28    41    
  T                                             **0.000**                       0.263
  Tx                0                     0                          0     0     
  T0                2                     0                          1     0     
  T1                232                   21                         33    20    
  T2                172                   35                         20    28    
  T3                11                    15                         8     14    
  T4                21                    13                         11    11    
  N                                             **0.000**                       0.735
  Nx                0                     0                          0     0     
  N0                376                   27                         27    25    
  N1                32                    20                         27    15    
  N2                28                    36                         19    32    
  N3                2                     1                          0     1     

Bold indicates the significance value (*P* \< 0.05).
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To explore the optimal treatment for stage I, II, and III LCNEC patients, we then compared the prognoses of the three groups (surgery combining with chemotherapy, surgery combining with radiation, and surgery combining with chemoradiation), respectively. We found, compared with the combination treatment of surgery and radiation, surgery combining with chemotherapy showed advantage to improve patients' prognoses (Figure [2](#cam42188-fig-0002){ref-type="fig"}C, Table [6](#cam42188-tbl-0006){ref-type="table"}); however, addition of radiation did not achieve better prognosis (Figur[2](#cam42188-fig-0002){ref-type="fig"}D‐F, Table [7](#cam42188-tbl-0007){ref-type="table"}). The results demonstrated that the optimal treatment for stage I, II, and III LCNEC patients was surgery combining with chemotherapy.

###### 

Characteristics among surgery combining with radiation (S + R) and surgery combining with chemotherapy (S + C) in stage I, II, and III LCNEC patients

  Characteristics   Before PSM analysis   *P*   
  ----------------- --------------------- ----- -------
  Race                                          0.716
  White             16                    167    
  Black             2                     20     
  Others            2                     8      
  Age                                           0.164
  ≥60               15                    115    
  ＜60              5                     80     
  Gender                                        0.061
  Male              7                     111    
  Female            13                    84     
  Grade                                         0.199
  I                 0                     0      
  II                0                     4      
  III               9                     108    
  IV                5                     45     
  Unknown           6                     38     
  TNM                                           0.260
  Stage I           13                    107    
  Stage II          2                     47     
  Stage III         5                     41     
  T                                             0.833
  Tx                0                     1      
  T0                0                     0      
  T1                7                     52     
  T2                7                     115    
  T3                5                     13     
  T4                1                     14     
  N                                             0.338
  Nx                0                     0      
  N0                15                    112    
  N1                4                     45     
  N2                1                     27     
  N3                0                     1      
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###### 

Characteristics among surgery combining with chemotherapy (S + C) and surgery combining with chemoradiation (S + C + R) in stage I, II, and III LCNEC patients before and after propensity score matching

  Characteristics   Before PSM analysis   *p*   After PSM analysis   *P*        
  ----------------- --------------------- ----- -------------------- ----- ---- -----------
  Race                                          0.691                           0.633
  White             167                   73                         66    64    
  Black             20                    7                          4     5     
  Others            8                     4                          3     4     
  Age                                           0.932                           0.407
  ≥60               115                   50                         39    44    
  ＜60              80                    34                         34    29    
  Gender                                        0.881                           0.511
  Male              111                   47                         35    39    
  Female            84                    37                         38    34    
  Grade                                         0.795                           0.488
  I                 0                     1                          0     1     
  II                4                     2                          2     2     
  III               108                   51                         48    46    
  IV                45                    13                         12    10    
  Unknown           38                    17                         11    14    
  TNM                                           **0.000**                       0.287
  Stage I           107                   11                         11    11    
  Stage II          47                    26                         37    24    
  Stage III         41                    47                         25    38    
  T                                             **0.015**                       **0.000**
  Tx                1                     0                          0     0     
  T0                0                     0                          0     0     
  T1                52                    21                         32    14    
  T2                115                   35                         29    33    
  T3                13                    15                         11    14    
  T4                14                    13                         1     12    
  N                                             **0.000**                       0.065
  Nx                0                     0                          0     0     
  N0                122                   27                         18    25    
  N1                45                    20                         34    19    
  N2                27                    36                         21    28    
  N3                1                     1                          0     1     

Bold indicates the significance value (*P* \< 0.05).
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Although surgery benefit stage I, II, and III LCNEC patients' prognoses, there were still some patients did not perform surgery (Table [4](#cam42188-tbl-0004){ref-type="table"}). To achieve better prognosis for non‐surgery stage I, II, and III patients, we compared the effect of palliative treatment, radiation, chemotherapy, and chemoradiation for those patients; the prognoses of the under treated patients were better than the palliative treatment group (Figure [S3](#cam42188-sup-0001){ref-type="supplementary-material"}A‐F, Tables [S6‐S8](#cam42188-sup-0001){ref-type="supplementary-material"}). There was no difference between chemotherapy and radiation in proving patients' prognoses (Figure [3](#cam42188-fig-0003){ref-type="fig"}A,B, Table [8](#cam42188-tbl-0008){ref-type="table"}). Combination treatment of radiation and chemotherapy achieved better prognosis than chemotherapy alone (Figure [3](#cam42188-fig-0003){ref-type="fig"}C,D, Table [9](#cam42188-tbl-0009){ref-type="table"}). Interestingly, when compared the combination treatment of radiation and chemotherapy with radiation alone, the combination treatment did not show advantage to achieve better prognoses for patients (Figure [S4](#cam42188-sup-0001){ref-type="supplementary-material"}A,B, Table [S9](#cam42188-sup-0001){ref-type="supplementary-material"}).

![The effect of treatments in non‐surgical stage I, II, and III LCNEC patients. A, Radiation achieved better benefit than chemotherapy for the non‐surgical stage I, II, and III LCNEC patients (*P* = 0.023). B, After the differences of variables between the groups were reduced, compared with chemotherapy, radiation did not showed advantage in proving patients' prognoses (*P* = 0.839). C, Chemoradiation achieved better prognosis than chemotherapy alone (*P* = 0.000). D, Chemoradiation showed advantage than chemotherapy in improving patients' prognoses after PSM method was conducted (*P* = 0.003)](CAM4-8-2979-g003){#cam42188-fig-0003}

###### 

Characteristics among chemotherapy (C) and radiation (R) in stage I, II, and III LCNEC patients before and after propensity score matching

  Characteristics   Before PSM analysis   *P*   After PSM analysis   *P*        
  ----------------- --------------------- ----- -------------------- ----- ---- -------
  Race                                          0.751                           0.883
  White             54                    70                         33    33    
  Black             11                    16                         6     7     
  Others            3                     5                          2     1     
  Age                                           0.224                           0.538
  ≥60               55                    66                         32    34    
  ＜60              13                    25                         9     7     
  Gender                                        0.280                           0.513
  Male              36                    56                         23    20    
  Female            32                    35                         18    21    
  Grade                                         0.277                           0.243
  I                 1                     0                          1     0     
  II                1                     1                          0     0     
  III               21                    32                         13    16    
  IV                6                     15                         4     7     
  Unknown           39                    43                         23    18    
  TNM                                           **0.000**                       0.888
  Stage I           32                    6                          6     6     
  Stage II          3                     6                          3     2     
  Stage III         33                    79                         32    33    
  T                                             **0.000**                       0.610
  Tx                6                     7                          6     1     
  T0                1                     0                          1     0     
  T1                21                    6                          7     3     
  T2                21                    23                         8     14    
  T3                3                     8                          3     2     
  T4                16                    47                         16    21    
  N                                             **0.000**                       0.737
  Nx                1                     2                          1     2     
  N0                36                    17                         10    10    
  N1                2                     4                          2     3     
  N2                21                    43                         20    15    
  N3                8                     25                         8     11    

Bold indicates the significance value (*P* \< 0.05).

John Wiley & Sons, Ltd

###### 

Characteristics among chemotherapy (C) and chemoradiation (C + R) in stage I, II, and III LCNEC patients before and after propensity score matching

  Characteristics   Before PSM analysis   *P*   After PSM analysis   *P*        
  ----------------- --------------------- ----- -------------------- ----- ---- -------
  Race                                          0.503                           0.846
  White             70                    174                        69    68    
  Black             16                    33                         15    16    
  Others            5                     8                          5     5     
  Age                                           0.521                           0.203
  ≥60               66                    148                        64    56    
  ＜60              25                    67                         25    33    
  Gender                                        0.223                           0.650
  Male              56                    116                        54    51    
  Female            35                    99                         35    38    
  Grade                                         0.178                           0.754
  I                 0                     1                          0     1     
  II                1                     1                          1     1     
  III               32                    68                         30    35    
  IV                15                    22                         15    10    
  Unknown           43                    123                        43    42    
  TNM                                           0.185                           0.675
  Stage I           6                     21                         6     4     
  Stage II          6                     6                          6     5     
  Stage III         79                    188                        77    80    
  T                                             **0.019**                       0.947
  Tx                7                     12                         7     7     
  T0                0                     2                          0     0     
  T1                6                     38                         6     6     
  T2                23                    59                         23    21    
  T3                8                     17                         8     13    
  T4                47                    87                         45    42    
  N                                             0.566                           1.000
  Nx                2                     2                          2     0     
  N0                17                    42                         15    20    
  N1                4                     8                          4     7     
  N2                43                    124                        43    45    
  N3                25                    39                         25    17    

Bold indicates the significance value (*P* \< 0.05).
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3.5. Chemotherapy alone benefited stage IV LCNEC patients more than the other treatments {#cam42188-sec-0015}
----------------------------------------------------------------------------------------

As shown in Table [4](#cam42188-tbl-0004){ref-type="table"}, the main treatments for stage IV patients were palliative treatment, chemotherapy, radiation, and chemoradiation, we attempted to explore the better treatment for the late stage patients. Compared with palliative treatment, chemotherapy achieved better OS (Figure [4](#cam42188-fig-0004){ref-type="fig"}A). To reduce the difference of variable between the groups (age, *P* = 0.030), PSM method was conducted, 308 patients were matched. After PSM, variables between the two groups had no significant differences (Table [10](#cam42188-tbl-0010){ref-type="table"}). Chemotherapy treatment has longer OS than palliative treatment (Figure [4](#cam42188-fig-0004){ref-type="fig"}B). Furthermore, radiation (Figure [S4](#cam42188-sup-0001){ref-type="supplementary-material"}C, Table [S10](#cam42188-sup-0001){ref-type="supplementary-material"}) and chemoradiation (Figure [S4](#cam42188-sup-0001){ref-type="supplementary-material"}D, Table [S11](#cam42188-sup-0001){ref-type="supplementary-material"}) also achieved better prognoses than palliative treatment.

![Chemotherapy alone achieved better prognosis than the other treatments in Stage IV LCNEC patients. A, Chemotherapy achieved better prognosis than palliative treatment (*P* = 0.000). B, Chemotherapy achieved better prognosis than palliative treatment after PSM was conducted (*P* = 0.000). C, Chemotherapy achieved better prognosis than radiation treatment (*P* = 0.000). D, Chemoradiation achieved better prognosis than radiation (*P* = 0.000). E, Chemoradiation achieved better prognosis than radiation after PSM was conducted (*P* = 0.000). F, Chemoradiation did not have advantage than chemotherapy alone in proving patients' prognoses (*P* = 0.688)](CAM4-8-2979-g004){#cam42188-fig-0004}

###### 

Characteristics among palliative treatment (P) and chemotherapy (C) in stage IV LCNEC patients before and after propensity score matching

  Characteristics   Before PSM analysis   *P*   After PSM analysis   *P*         
  ----------------- --------------------- ----- -------------------- ----- ----- -------
  Race                                          0.536                            0.789
  White             294                   292                        266   267    
  Black             31                    35                         30    27     
  Others            12                    16                         12    14     
  Age                                           **0.030**                        0.843
  ≥60               271                   254                        243   245    
  ＜60              66                    92                         65    63     
  Gender                                        0.842                            0.934
  Male              203                   211                        194   193    
  Female            134                   135                        114   115    
  Grade                                         0.067                            0.604
  I                 0                     4                          0     4      
  II                1                     2                          1     0      
  III               67                    87                         66    74     
  IV                23                    30                         21    23     
  Unknown           247                   223                        220   207    
  T                                             0.970                            1.000
  Tx                54                    60                         50    50     
  T0                4                     3                          4     3      
  T1                34                    29                         30    24     
  T2                80                    93                         76    84     
  T3                13                    13                         12    12     
  T4                152                   148                        136   135    
  N                                             0.654                            1.000
  Nx                35                    21                         31    18     
  N0                58                    54                         49    67     
  N1                31                    24                         30    21     
  N2                149                   157                        139   140    
  N3                64                    90                         59    82     

Bold indicates the significance value (*P* \< 0.05).
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To determine which one of the treatments (chemotherapy, radiation, chemoradiation) benefits more for the late stage patients, we firstly compared radiation with chemotherapy. Chemotherapy benefited patients more than radiation (Figure [4](#cam42188-fig-0004){ref-type="fig"}C, Table [11](#cam42188-tbl-0011){ref-type="table"}). Then, we compared radiation with chemoradiation after PSM, 184 patients were matched (Table [S12](#cam42188-sup-0001){ref-type="supplementary-material"}). As shown in Figure [4](#cam42188-fig-0004){ref-type="fig"}D,E, chemoradiation obtained better benefit than radiation alone. While compared with chemotherapy alone, the combination treatment chemoradiation did not achieve more benefit (Figure [4](#cam42188-fig-0004){ref-type="fig"}F, Figure [S4](#cam42188-sup-0001){ref-type="supplementary-material"}E, Table [S13](#cam42188-sup-0001){ref-type="supplementary-material"}). The results demonstrated that chemotherapy alone was the better treatment than palliative treatment, radiation, and chemoradiation for the stage IV LCNEC patients.

###### 

Characteristics among radiation (R) and chemotherapy (C) in stage IV LCNEC patients before propensity score matching

  Characteristics   Before PSM analysis   *P*   
  ----------------- --------------------- ----- -------
  Race                                          0.301
  White             151                   292    
  Black             24                    35     
  Others            9                     16     
  Age                                           0.503
  ≥60               140                   254    
  ＜60              44                    92     
  Gender                                        0.111
  Male              99                    211    
  Female            85                    135    
  Grade                                         0.565
  I                 0                     4      
  II                1                     2      
  III               42                    87     
  IV                14                    30     
  Unknown           127                   223    
  T                                             0.384
  Tx                23                    60     
  T0                3                     3      
  T1                19                    29     
  T2                49                    93     
  T3                10                    13     
  T4                80                    148    
  N                                             0.066
  Nx                13                    21     
  N0                47                    54     
  N1                16                    24     
  N2                77                    157    
  N3                31                    90     

John Wiley & Sons, Ltd

4. DISCUSSION {#cam42188-sec-0016}
=============

The optimal treatment strategies for LCNEC patients have not yet been established. In order to improve prognoses in patients with LCNEC, this study investigated the effect of different treatments based on the data obtained from the SEER database. We found that age, gender, TNM stage, T stage, N stage, and M stage were all independent prognostic factors. Surgery benefited stage I, II, and III LCNEC patients' prognoses. Surgery combining with chemotherapy was the optimal treatment for stage I, II, and III LCNEC patients. Chemotherapy alone achieved better prognosis than palliative treatment, radiation, or chemoradiation for stage IV LCNEC patients.

Surgical treatment can achieve satisfactory results for suitable patients. As for LCNEC, the patients who suit to perform surgery have no standard by now. Surgical resection was indicated for stage I and II patients to obtain better prognosis.[5](#cam42188-bib-0005){ref-type="ref"} However, the 1‐year OS rate of stage I, II, and III ALCNEC patients who underwent surgery was better (88.9%) than those who did not undergo surgery (51.9%).[6](#cam42188-bib-0006){ref-type="ref"} Except the stages reported before, in this study, we also found stage III B LCNEC patients achieved benefit upon surgical treatment. Comparing with previous studies, tumor patients exhibiting both LCNEC and the other kind of tumors as well as the lung metastasis tumors were removed; all the patients analyzed in this study were pure LCNEC patients. Moreover, a bigger cohort of patients was analyzed, and the differences of variables between the groups that may influence the effect of surgery for patients' prognoses were reduced. Thus, we demonstrate that stage I, II, and III LCNEC patients should perform surgery to achieve better prognosis.

LCNEC is an aggressive tumor with high rate of recurrence even after complete surgical resection in its early stage;[7](#cam42188-bib-0007){ref-type="ref"} therefore, surgery alone is not sufficient to treat patients with LCNEC, and adjuvant treatment such as chemotherapy or radiation is necessary. Prophylactic cranial irradiation could decrease the incidence of brain metastasis and improve survival rate in patients with SCLC.[8](#cam42188-bib-0008){ref-type="ref"} Pulmonary neuroendocrine carcinoma patients with brain metastasis could be effectively treated with either whole‐brain radiation therapy or stereotactic radiosurgery (SRS).[9](#cam42188-bib-0009){ref-type="ref"} However, radiation did not make any benefit in improving LCNEC patients' prognosis.[10](#cam42188-bib-0010){ref-type="ref"} Chemoradiation achieved better overall response rate than chemotherapy alone;[11](#cam42188-bib-0011){ref-type="ref"} unlike the result found in literature, in our study, we found that chemoradiation did not make may benefit in proving stage I, II, and III surgery patients' prognoses or stage IV patients' prognoses. The effect of radiation for LCNEC patients is limited and should be reconsidered thoroughly. Contrast with radiation, chemotherapy showed significant advantage. For example, when patients were diagnosed at stage I, II, and III, surgery combining with chemotherapy was the optimal treatment; in stage IV patients, chemotherapy alone achieved better prognosis than the others treatment. Our study demonstrated advantageous position of chemotherapy in improving patients' prognoses for LCNEC.

In conclusion, through this study, we recommend that stage I, II, and III LCNEC patients should perform surgery to obtain better prognoses, surgery combining with chemotherapy is the optimal treatment for stage I, II, and III LCNEC patients, and chemotherapy alone is better than the other treatments for stage IV patients.
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